Lakefront Biotherapeutics (GLPGF) FCF Margin Growth (3y) (2017 - 2026)
Powered by 
Analysis
Lakefront Biotherapeutics (GLPGF) FCF Margin Growth (3y) (2017 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 210.97 Bn | 196.98 Bn | 7.24 Bn | -2,024.00 |
| 2 | Gilead Sciences | 180.98 Bn | 177.80 Bn | 6.22 Bn | 1,067.00 |
| 3 | Vertex Pharmaceuticals | 132.09 Bn | 124.24 Bn | 2.84 Bn | -1,272.00 |
| 4 | Regeneron Pharmaceuticals | 82.56 Bn | 74.57 Bn | 3.93 Bn | -2,228.00 |
| 5 | Argenx Se | 61.71 Bn | 56.53 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.60 Bn | 49.46 Bn | 52.00 Mn | -5,426.00 |
| 7 | Alnylam Pharmaceuticals | 34.02 Bn | 30.71 Bn | 992.69 Mn | 4,612.00 |
| 8 | Biogen | 31.25 Bn | 29.97 Bn | 1.96 Bn | -203.00 |
| 9 | Roivant Sciences | 29.76 Bn | 29.76 Bn | 1.16 Mn | -1.75 Mn |
| 10 | Lakefront Biotherapeutics | 1.73 Bn | 1.73 Bn | 3.51 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -112,023.00 |
| Dec 31, 2025 | -28,521.00 |
| Mar 31, 2025 | -598.00 |
| Dec 31, 2024 | -68,223.00 |
| Jun 30, 2024 | 3,758.00 |
| Mar 31, 2024 | -9,114.00 |
| Dec 31, 2023 | 135.00 |
| Mar 31, 2023 | -9,097.00 |
| Dec 31, 2022 | 29,116.00 |
| Mar 31, 2022 | 17,188.00 |
| Dec 31, 2021 | 67,564.00 |
| Jun 30, 2021 | 4,918.00 |
| Mar 31, 2021 | 289.00 |
| Dec 31, 2020 | 28,880.00 |
| Jun 30, 2020 | 18.19 Mn |
| Mar 31, 2020 | 79.00 |
| Dec 31, 2019 | -2,837.00 |
| Jun 30, 2019 | -4,604.00 |
| Mar 31, 2019 | -270,611.00 |
| Dec 31, 2018 | 4,175.00 |